Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more
Market Cap & Net Worth: Jubilant Pharmova Limited (JUBLPHARMA)
Jubilant Pharmova Limited (NSE:JUBLPHARMA) has a market capitalization of $1.54 Billion (₹133.02 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #9288 globally and #377 in its home market, demonstrating a 2.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jubilant Pharmova Limited's stock price ₹839.95 by its total outstanding shares 158369748 (158.37 Million).
Jubilant Pharmova Limited Market Cap History: 2015 to 2026
Jubilant Pharmova Limited's market capitalization history from 2015 to 2026. Data shows growth from $602.85 Million to $1.54 Billion (9.97% CAGR).
Index Memberships
Jubilant Pharmova Limited is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.05% | #322 of 500 |
|
NIFTY ALHPA 50
NIFTYALI
|
$166.87 Billion | 0.37% | #35 of 47 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.12% | #229 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.04% | #332 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.43 Billion | 0.33% | #111 of 250 |
Weight: Jubilant Pharmova Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jubilant Pharmova Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jubilant Pharmova Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Jubilant Pharmova Limited's market cap is 0.03 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.23x
Jubilant Pharmova Limited's market cap is 0.23 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $924.37 Million | $57.49 Billion | $3.92 Billion | 0.02x | 0.24x |
| 2017 | $1.17 Billion | $58.61 Billion | $5.76 Billion | 0.02x | 0.20x |
| 2018 | $1.06 Billion | $75.18 Billion | $6.43 Billion | 0.01x | 0.16x |
| 2019 | $808.24 Million | $91.11 Billion | $5.74 Billion | 0.01x | 0.14x |
| 2020 | $1.28 Billion | $59.76 Billion | $8.98 Billion | 0.02x | 0.14x |
| 2021 | $1.04 Billion | $60.99 Billion | $8.36 Billion | 0.02x | 0.12x |
| 2022 | $672.92 Million | $61.30 Billion | $4.14 Billion | 0.01x | 0.16x |
| 2023 | $990.19 Million | $62.82 Billion | -$610.00 Million | 0.02x | N/A |
| 2024 | $2.02 Billion | $67.03 Billion | $771.00 Million | 0.03x | 2.62x |
| 2025 | $1.96 Billion | $72.34 Billion | $8.39 Billion | 0.03x | 0.23x |
Competitor Companies of JUBLPHARMA by Market Capitalization
Companies near Jubilant Pharmova Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Jubilant Pharmova Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Jubilant Pharmova Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Jubilant Pharmova Limited's market cap moved from $602.85 Million to $ 1.54 Billion, with a yearly change of 9.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹1.54 Billion | -21.74% |
| 2025 | ₹1.96 Billion | -2.89% |
| 2024 | ₹2.02 Billion | +104.11% |
| 2023 | ₹990.19 Million | +47.15% |
| 2022 | ₹672.92 Million | -35.08% |
| 2021 | ₹1.04 Billion | -19.19% |
| 2020 | ₹1.28 Billion | +58.70% |
| 2019 | ₹808.24 Million | -23.45% |
| 2018 | ₹1.06 Billion | -9.52% |
| 2017 | ₹1.17 Billion | +26.24% |
| 2016 | ₹924.37 Million | +53.33% |
| 2015 | ₹602.85 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Jubilant Pharmova Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.54 Billion USD |
| MoneyControl | $1.54 Billion USD |
| MarketWatch | $1.54 Billion USD |
| marketcap.company | $1.54 Billion USD |
| Reuters | $1.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.